SER-109 significantly reduced rCDI rates through week 24 with an observed safety profile comparable to placebo.Clinical trial information: NCT03183128.Cumulative rCDI rates, relative risks, and rate differences at weeks 4, 8, 12 and 24.TimepointSER-109N=89PlaceboN=93Relative Risk(95% CI)Rate ...
109 group and placebo, following a course of antibiotic therapy, and the phase 3 data look great. They met their primary end point in the SER-109 arm, about 88% of patients had clinical resolution without recurrence at 8 weeks compared to about 60% in the placebo group. This equates to...
SER-100 is under investigation in clinical trial NCT01987284 (SER100 in Isolated Systolic Hypertension). Type Small Molecule Groups Investigational Structure Download Similar Structures Weight Average: 1781.237 Monoisotopic: 1780.110046948 Chemical Formula ...
109. Sharon E, Paolino JS, Kaplan D (1972) "Hematemesis after reserpine for Raynaud's phenomenon." Ann Intern Med, 77, p. 479-80 110. Widmer RB (1985) "Reserpine: the maligned antihypertensive drug." J Fam Pract, 20, p. 81-3 111. Combs RM (1967) "Unusual response to reserpine ...
2022 Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerThe ASTRUM-005 Randomized Clinical Trial Ying Cheng, MD1; Liang Han, MD2; Lin Wu, PhD3; et al Jun Chen, PhD4; Hongmei Sun, BS5; Guilan Wen, MMed...
15 At the outset of the trial, we attempted to mitigate this potential by decreasing the doses of cisplatin and gemcitabine in the arm including berzosertib. This action alone may have dissipated the clinical impact of berzosertib; as noted, the cumulative doses of cisplatin were significantly...
Apoptosis signal-regulating kinase 1 (ASK1) is a protein that plays a role in apoptosis under conditions ofoxidative stress.65Selonsertibis anASK1inhibitor that has been developed for the treatment of steatohepatitis. In a phase II clinical trial, 43% of the patients treated with selonsertib ...
the direct delivery of toxic agents to cancer cells, minimizing damage to healthy cells and potentially reducing side effects compared to traditional chemotherapy. The ADC market is rapidly growing , with several ADCs already approved by regulatory agencies worldwide and many more in clinical ...
ERK1/2 at the end of the MAPK signaling pathway carries out cellular processes and is targeted to overcome acquired resistance of upstream kinase inhibitors [108,109]. To date, two ERK1/2 inhibitors have reached clinical trials (Phase I or I/IIa). BVD-523 is an ATP competitive selective...
19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical TrialBACKGROUND. Following standard of care antibiotics, investigational...